18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis

Chun Yi Lin, Jin Hua Chen, Ji An Liang, Cheng Chieh Lin, Long Bin Jeng, Chia Hung Kao

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6%, 98.0%, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7%, 88.9%, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.

Original languageEnglish
Pages (from-to)2417-2422
Number of pages6
JournalEuropean Journal of Radiology
Volume81
Issue number9
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Meta-Analysis
Hepatocellular Carcinoma
Neoplasm Metastasis
Glucose
Sensitivity and Specificity
MEDLINE
ROC Curve

Keywords

  • FDG PET
  • Meta-analysis
  • Metastatic HCC
  • Recurrent HCC
  • Systematic review

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma : A systematic review and meta-analysis. / Lin, Chun Yi; Chen, Jin Hua; Liang, Ji An; Lin, Cheng Chieh; Jeng, Long Bin; Kao, Chia Hung.

In: European Journal of Radiology, Vol. 81, No. 9, 09.2012, p. 2417-2422.

Research output: Contribution to journalArticle

Lin, Chun Yi ; Chen, Jin Hua ; Liang, Ji An ; Lin, Cheng Chieh ; Jeng, Long Bin ; Kao, Chia Hung. / 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma : A systematic review and meta-analysis. In: European Journal of Radiology. 2012 ; Vol. 81, No. 9. pp. 2417-2422.
@article{3d4d96a810c44eeda1ad1cd9be5e4e43,
title = "18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis",
abstract = "Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6{\%}, 98.0{\%}, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7{\%}, 88.9{\%}, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.",
keywords = "FDG PET, Meta-analysis, Metastatic HCC, Recurrent HCC, Systematic review",
author = "Lin, {Chun Yi} and Chen, {Jin Hua} and Liang, {Ji An} and Lin, {Cheng Chieh} and Jeng, {Long Bin} and Kao, {Chia Hung}",
year = "2012",
month = "9",
doi = "10.1016/j.ejrad.2011.08.004",
language = "English",
volume = "81",
pages = "2417--2422",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "9",

}

TY - JOUR

T1 - 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma

T2 - A systematic review and meta-analysis

AU - Lin, Chun Yi

AU - Chen, Jin Hua

AU - Liang, Ji An

AU - Lin, Cheng Chieh

AU - Jeng, Long Bin

AU - Kao, Chia Hung

PY - 2012/9

Y1 - 2012/9

N2 - Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6%, 98.0%, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7%, 88.9%, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.

AB - Aim: Positron emission tomography (PET) using F18-flurodeoxy-glucose (FDG) has been widely used for reflecting cellular metabolism. However, the feasibility of FDG PET in the diagnosis of hepatocellular carcinoma (HCC) is limited. The aim of the study was to assess the ability of FDG PET (PET/CT) in the detection of extrahepatic metastases or recurrent HCC. Materials and methods: We conducted MEDLINE, EMBASE and COCHRANE searches (last update, April 2011). Eight eligible articles were identified evaluating F18-FDG PET (PET/CT) in extrahepatic metastases or recurrent HCC. Two authors independently evaluated the methodological quality of each study. We estimated pooled sensitivities, specificities, summary receiver-operating-characteristic (SROC) curves, and summary likelihood ratios. Results: Eight eligible studies were enrolled in this study. The pooled estimates of sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of FDG PET (PET/CT) in the detection of metastatic HCC were 76.6%, 98.0%, 14.68, and 0.28, respectively. The pooled estimates of sensitivity, specificity, LR+ and LR- of FDG PET (PET/CT) in the detection of recurrent HCC were 81.7%, 88.9%, 4.72, and 0.19, respectively. Conclusion: Based on the results of this systematic review, F-18 FDG PET (PET/CT) was useful in ruling in extrahepatic metastases of HCC and valuable for ruling out the recurrent HCC.

KW - FDG PET

KW - Meta-analysis

KW - Metastatic HCC

KW - Recurrent HCC

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84864695666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864695666&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2011.08.004

DO - 10.1016/j.ejrad.2011.08.004

M3 - Article

C2 - 21899970

AN - SCOPUS:84864695666

VL - 81

SP - 2417

EP - 2422

JO - European Journal of Radiology

JF - European Journal of Radiology

SN - 0720-048X

IS - 9

ER -